Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Licensed Technology (Tables)

Licensed Technology (Tables)

3 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Licensed technology consists of the following:

	March 31,		December 31,
	2018		2017
Licensed technology	$	4,608,000	$	4,608,000
Less accumulated amortization		718,000		631,000
Licensed technology, net	$	3,890,000	$	3,977,000

Intangible assets consist of the following (in thousands):

	March 31, 2018				December 31, 2017
	Gross carrying value		Accumulated amortization		Gross carrying value		Accumulated Amortization
Amortizable intangible assets
Licensed technology	$	4,608	$	718	$	4,608	$	631

Schedule of Finite-lived Intangible Assets Amortization Expense

Amortization expense related to intangible assets totaled $87,000 for the three months ended March 31, 2018 and totaled $203,000 for the three ended March 31, 2017. The aggregate estimated amortization expense for intangible assets remaining as of March 31, 2018 is as follows (in thousands):

2018	$	259
2019		346
2020		346
2021		346
2022		346
over 5 years		2,247

Total	$	3,890